Solara Active Pharma Sciences Ltd
Solara Active Pharma Q2 FY27 Revenue up 33% to INR 4,178 Mn; EBITDA Doubles
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 16 Oct 2026, 01:48 PM IST · BSE ID: e3ae941b-3890-4ef1-a02c-8e39b45e84b1
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's second-quarter revenue grew 33%, and operating profit more than doubled, reaching its best quarter in five years.
🤖 AI Summary
- Solara Active Pharma Q2 FY27 revenue increased 33% YoY to INR 4,178 Mn.
- Overall EBITDA more than doubled to INR 769 Mn, highest in the last five years.
- Base business revenue grew 37% YoY to INR 3,273 Mn with EBITDA up 68% to INR 771 Mn.
- Ibuprofen business revenue rose 21% YoY to INR 905 Mn, EBITDA loss narrowed to INR 2 Mn.
- Net debt reduced by INR 1,141 Mn in H1 FY27 to INR 5,000 Mn by September 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Overall Revenue Q2 FY27
INR 4,178 Mn
33%
Overall EBITDA Q2 FY27
INR 769 Mn
118%
Base Business Revenue Q2 FY27
INR 3,273 Mn
37%
Ibuprofen Revenue Q2 FY27
INR 905 Mn
21%
Net Debt Sep'26
INR 5,000 Mn
EPS Q2 FY27
INR 5.92 per share
🏢 How This Affects the Company
Overall revenue increased to INR 4,178 Mn, driven by 37% growth in the base business and 21% growth in the ibuprofen segment. The ibuprofen business is nearing breakeven, improving the overall business profile.
EBITDA more than doubled to INR 769 Mn, and PAT swung to INR 285 Mn from a loss of INR 101 Mn in Q2 FY26. Net debt reduced by 19% to INR 5,000 Mn, improving net debt to EBITDA to 1.8x.
The base business maintained its growth momentum with 78% of revenues from regulated markets. The ibuprofen business's improved profitability reflects better price realisations and higher volumes.
The narrowing of losses in the ibuprofen business reduces a previous financial drag on the company. The reduction in net debt also decreases financial leverage risk.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results update.
👤
Who Is Affected
Shareholders are affected by the improved financial performance, including an increase in earnings per share to INR 5.92 in Q2 FY27 from a loss of INR 2.36 in Q2 FY26.
🔍
Management Signal
Management intends to continue investing in growth and is in an advanced stage of a strategic review for the Ibuprofen business, with an update expected within 12 weeks.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Update on Ibuprofen business strategic review within 12 weeks
Q3 FY27 financial results — check revenue and EBITDA growth continuation
Any further announcements regarding debt reduction or capital expenditure plans
MEDIUM RISK
Ibuprofen business remains in loss, and base business gross margins faced pressure from input costs.
💡 Investor Takeaway
Solara Active Pharma's Q2 FY27 consolidated revenue grew 33% to INR 4,178 Mn YoY. Overall EBITDA more than doubled to INR 769 Mn, reaching its highest in five years, while PAT was INR 285 Mn against a loss of INR 101 Mn a year ago.
⚖️ Strengths & Concerns
✅ Positives
- Overall EBITDA increased 118% YoY to INR 769 Mn in Q2 FY27, marking the highest quarterly EBITDA in five years.
- Net debt decreased by INR 1,141 Mn in H1 FY27 to INR 5,000 Mn, improving net debt to EBITDA to 1.8x from 3.2x.
⚠️ Concerns
- Ibuprofen business continues to report an EBITDA loss of INR 2 Mn in Q2 FY27, operating in a challenging environment.
- Base business gross margins decreased to 50.3% in Q2 FY27 from 53.2% in Q2 FY26 due to continued input cost pressures.
📅 Company Track Record
Solara Active Pharma reported consolidated net profit of Rs. 28.46 Crores and revenue of Rs. 417.34 Crores in a previous Q2 FY27 filing. Q1 FY27 consolidated net profit was Rs. 16.31 Crores, up 55.04% YoY.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Solara Active Pharma Sciences' overall revenue in Q2 FY27?
Solara Active Pharma Sciences reported an overall revenue of INR 4,178 Mn in Q2 FY27, an increase of 33% YoY and 9% QoQ.
How much did Solara's EBITDA grow in Q2 FY27?
The overall EBITDA for Solara Active Pharma Sciences grew 118% YoY and 21% QoQ to INR 769 Mn in Q2 FY27.
What was the PAT for Solara Active Pharma Sciences in Q2 FY27?
Solara Active Pharma Sciences recorded a Profit After Tax (PAT) of INR 285 Mn in Q2 FY27, against a loss of INR 101 Mn in Q2 FY26.
What is the status of Solara's Ibuprofen business in Q2 FY27?
The Ibuprofen business revenue was INR 905 Mn, up 21% YoY, and its EBITDA loss narrowed to INR 2 Mn in Q2 FY27 from INR 87 Mn in Q1 FY27.
What was Solara Active Pharma Sciences' net debt as of September 2026?
Net debt for Solara Active Pharma Sciences was INR 5,000 Mn as of September 2026, a reduction of INR 1,141 Mn during H1 FY27.
Questions based on this BSE filing only. For information purposes.